Ondine Biomedical Inc Asset Resilience Ratio
Ondine Biomedical Inc asset resilience ratio. Ondine Biomedical Inc (OBI) has an Asset Resilience Ratio of 39.85% as of September 2008. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Ondine Biomedical Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ondine Biomedical Inc (2006–2007)
Asset resilience ratio of Ondine Biomedical Inc from 2006 to 2007. This chart shows how Ondine Biomedical Inc's Asset Resilience Ratio has changed over time. Read how much debt does Ondine Biomedical Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ondine Biomedical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see OBI total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX1.88 Million | 39.85% |
| Total Liquid Assets | GBX1.88 Million | 39.85% |
Asset Resilience Insights
- Very High Liquidity: Ondine Biomedical Inc maintains exceptional liquid asset reserves at 39.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ondine Biomedical Inc Industry Peers by Asset Resilience Ratio
Compare Ondine Biomedical Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Ondine Biomedical Inc Asset Resilience Ratio by Year (2006–2007)
Ondine Biomedical Inc asset resilience ratio by year from 2006 to 2007. The table below shows the annual Asset Resilience Ratio data for Ondine Biomedical Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2007-12-31 | 43.12% | GBX5.61 Million ≈ $682.19 |
GBX13.00 Million ≈ $1.58K |
-15.66pp |
| 2006-12-31 | 58.78% | GBX10.85 Million ≈ $1.32K |
GBX18.46 Million ≈ $2.25K |
-- |
About Ondine Biomedical Inc
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfecti… Read more